Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Dose optimization and once‑daily potential
Richard outlines phase II dosing cohorts and plans to fine‑tune dose for phase III, including once‑daily regimens.
Play episode from 16:40
Transcript
